What is your treatment approach for patients with an IDH wild-type, low-grade glioma?

Our neuro-oncology group has begun using concurrent and adjuvant TMZ for patients with IDH wildtype. Our radonc group supports doses of 54 to 60Gy, favoring use of 60Gy on institutional protocol in order to assess the long-term outcomes.

Timely ASCO abstract from NRG/RTOG 9802:

http://abstracts.asco.org/239/AbstView_239_252343.html

Wild type did not seem to benefit from PCV, but TMZ not evaluated.